JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lambert, B.
Right arrow Articles by De Vos, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lambert, B.
Right arrow Articles by De Vos, F.

188Re-HDD/Lipiodol Therapy for Hepatocellular Carcinoma: A Phase I Clinical Trial

Bieke Lambert, MD1, Klaus Bacher, MSc2, Luc Defreyne, MD3, Filip Gemmel, MD1, Hans Van Vlierberghe, MD, PhD4, Jae Min Jeong, PhD5, Rudi A. Dierckx, MD, PhD1, Christophe Van de Wiele, MD, PhD1, Hubert Thierens, PhD2 and Filip De Vos, PhD1

1 Nuclear Medicine Division, Ghent University Hospital, Ghent, Belgium
2 Department of Medical Physics, Ghent University, Ghent, Belgium
3 Division of Interventional Radiology, Ghent University Hospital, Ghent, Belgium
4 Division of Gastroenterology, Ghent University Hospital, Ghent, Belgium
5 Department of Nuclear Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea



View larger version (19K):

[in a new window]
  		FIGURE 1. (A) Blood activity levels in percent of injected activity per milliliter blood (%IA/mL) as function of time after injection. (B) Cumulative urinary excretion of activity in percent of injected activity (%IA) plotted as function of time after injection.

 


View larger version (64K):

[in a new window]
  		FIGURE 2. Whole-body scans (right, anterior image; left, posterior image) of patient 4 performed 30 h after administration of 4.12 GBq 188Re-HDD/lipiodol. Significant uptake is seen in multifocal HCC and in bladder. Faint uptake is observed in lungs and no uptake is evident in thyroid or gastric mucosa.

 


View larger version (28K):

[in a new window]
  		FIGURE 3. (A) White blood cell counts before therapy and at week 6. (B) Platelet counts before therapy and at week 6. Dashed lines represent sessions 6a and 6b. (C) Bilirubin levels before therapy and at weeks 2 and 6 after therapy. (D) AST levels before therapy and at weeks 2 and 6 after therapy.

 


View larger version (12K):

[in a new window]
  		FIGURE 4. Change in serum {alpha}-fetoprotein from baseline values at week 6 in 8 treatment sessions with initially elevated tumor marker level.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.